Combining pembrolizumab with chemotherapy for relapsed Hodgkin lymphoma
Phase II Trial of Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma
PHASE2 · University of Cologne · NCT04838652
This study is testing if adding pembrolizumab to standard chemotherapy can help people with relapsed Hodgkin lymphoma feel better and have fewer side effects.
Quick facts
| Phase | PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 29 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | University of Cologne (other) |
| Drugs / interventions | pembrolizumab, chemotherapy |
| Locations | 1 site (Cologne) |
| Trial ID | NCT04838652 on ClinicalTrials.gov |
What this trial studies
This trial aims to evaluate the effectiveness and safety of pembrolizumab, an anti-PD-1 antibody, in combination with established chemotherapy regimens (ICE or DHAP) for patients with first-relapsed or refractory classical Hodgkin lymphoma. The study seeks to leverage the synergistic effects of checkpoint inhibition alongside conventional chemotherapy to create a more effective treatment option with reduced toxicity. By potentially replacing high-dose chemotherapy, this approach could improve patient outcomes and quality of life.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with histologically confirmed first relapse or primary refractory classical Hodgkin lymphoma.
Not a fit: Patients with nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma will not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a more effective and less toxic option for patients with relapsed or refractory classical Hodgkin lymphoma.
How similar studies have performed: Other studies have shown promising results with similar combinations of checkpoint inhibitors and chemotherapy, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed first relapse of cHL or primary refractory cHL Exclusion Criteria: * Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma
Where this trial is running
Cologne
- 1st Department of Medicine, Cologne University Hospital — Cologne, Germany (RECRUITING)
Study contacts
- Principal investigator: Andreas Engert, Prof. — 1st Department of Medicine, Cologne Universit Hospital
- Study coordinator: Michael Fuchs
- Email: ghsg@uk-koeln.de
- Phone: +49221478
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Classical Hodgkin Lymphoma